Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia

Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. However, resistance or intolerance to these TKIs still leaves some patients without many treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Kimberly E, Saleem, Najma, Lee, Georgina, Steinberg, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754816/
https://www.ncbi.nlm.nih.gov/pubmed/23986642
http://dx.doi.org/10.2147/OTT.S36980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754816/
https://www.ncbi.nlm.nih.gov/pubmed/23986642
http://dx.doi.org/10.2147/OTT.S36980

Ejemplares similares